SANDOSTATIN LAR

Información principal

  • Denominación comercial:
  • SANDOSTATIN LAR 20 mg MICROESFERAS PARA SUSPENSION INYECTABLE
  • Dosis:
  • 20 mg
  • formulario farmacéutico:
  • MICROGR
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático
  • Fabricado por:
  • SANDOZ, GMBH

Documentos

  • para el público en general:
  • El prospecto de información de este producto no está disponible actualmente, puede enviar una petición a nuestro servicio al cliente y le notificaremos tan pronto como nos sea posible para conseguirlo.


    Solicitar el prospecto de información al público.

Localización

  • Disponible en:
  • SANDOSTATIN LAR 20 mg MICROESFERAS PARA SUSPENSION INYECTABLE
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • Estado de Autorización:
  • VIGENTE
  • Número de autorización:
  • E.F.30.384
  • Fecha de autorización:
  • 21-04-1999
  • última actualización:
  • 03-09-2018
  • El prospecto de información de este producto no está disponible actualmente, puede enviar una petición a nuestro servicio al cliente y le notificaremos tan pronto como nos sea posible para conseguirlo.

    Solicitar el prospecto de información al público.

31-10-2018

Outcome of a public consultation on the draft guidance on the scientific requirements for health claims related to muscle function and physical performance

Outcome of a public consultation on the draft guidance on the scientific requirements for health claims related to muscle function and physical performance

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on a draft guidance on the scientific requirements for health claims related to muscle function and physical performance, prepared by the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), supported by the Working Group on Claims. The draft guidance was endorsed by the Panel for public consultation ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Published on: Tue, 30 Oct 2018 00:00:00 +0100 In compliance with Article 43 of Regulation (EC) No 396/2005, EFSA received a mandate from the European Commission to provide an update of the reasoned opinion on the review of existing maximum residue levels (MRLs) for imazalil published on 5 September 2017, taking into account the additional information provided on the toxicity of the metabolites R014821, FK‐772 and FK‐284. EFSA did not derive MRL proposals from the post‐harvest uses reported on citrus fru...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

9-10-2018

Notice of call for expressions of interest - Salmonella molecular serotyping

Notice of call for expressions of interest - Salmonella molecular serotyping

France - Agence Nationale du Médicament Vétérinaire

8-10-2018

Riesgo cardiovascular de los antiinflamatorios no esteroideos

Un problema que parecía ligado a algunos fármacos en particular, se extendió luego a toda la clase farmacológica. Es necesario tenerlo en cuenta antes de usar estos fármacos tan difundidos. Medicina (Buenos Aires), octubre de 2018

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

21-9-2018

Medicines Safety Update, Volume 9, Number 3, August-September 2018

TGA, 18 de septiembre de 2018 Medicines Safety Update es el boletín de seguridad de medicamentos de la Administración de Productos Terapéuticos (TGA), de Australia. Nuevas advertencias en las etiquetas de medicamentos que contienen agentes bloqueantes neuromusculares; Toxicidad sistémica de los anestésicos locales; Uso off-label de atropina

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

18-9-2018

Riesgos de los bloqueantes neuromusculares en cirugía

Los anestesistas deben equilibrar los beneficios potenciales del bloqueo neuromuscular con un mayor riesgo de complicaciones pulmonares postoperatorias. The Lancet Respiratory Medicine, 14 de septiembre de 2018

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

29-8-2018

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The EFSA Panel on Plant Protection Products and their Residues reviewed the guidance on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessment. The inclusion of aged sorption is a higher tier in the groundwater leaching assessment. The Panel based its review on a test with three substances taken from a data set provided by the European Crop Protection Association. Particular points of attention were the quali...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Explanatory note on the determination of newly expressed protein levels in the context of genetically modified plant applications for EU market authorisation

Explanatory note on the determination of newly expressed protein levels in the context of genetically modified plant applications for EU market authorisation

Published on: Mon, 20 Aug 2018 00:00:00 +0200 Genetically modified organisms are subject to a risk assessment and regulatory approval before entering the European market. According to legislation (Directive 2001/18/EC, Regulation (EC) No 1829/2003 and Regulation (EU) No 503/2013) and the EFSA guidance documents on the risk assessment of food and feed from genetically modified (GM) plants and on the environmental risk assessment of GM plants, applicants need to perform a molecular characterisation of any...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Outcome of the public consultation on a draft protocol for the Scientific Opinion on dietary sugars

Outcome of the public consultation on a draft protocol for the Scientific Opinion on dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on a draft protocol for the Scientific Opinion on free sugars from all dietary sources, prepared by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel), supported by the ad‐hoc Working Group on Sugars. The draft protocol was endorsed by the Panel for public consultation at its plenary meeti...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

10-8-2018

Spinraza (nusinersén): Hidrocefalia comunicante no asociada a meningitis ni a hemorragia

Biogen, AEMPS, Julio 2018 Biogen, de acuerdo con la Agencia Europea de Medicamentos (EMA) y con la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), dieron a conocer un comunicado en relación a este tema de seguridad sobre Spinraza, medicamento indicado para el tratamiento de la atrofia muscular espinal (AME) 5q que se administra por vía intratecal mediante punción lumbar.

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

26-7-2018

Opinion/decision on a Paediatric investigation plan (PIP):    Ninlaro, Ixazomib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): Ninlaro, Ixazomib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

18-7-2018

Orphan designation:  Lenvatinib,  for the: Treatment of papillary thyroid cancer

Orphan designation: Lenvatinib, for the: Treatment of papillary thyroid cancer

Europe - EMA - European Medicines Agency

4-6-2018

Un nuevo mecanismo molecular explica la persistencia del VIH

Un nuevo mecanismo molecular explica la persistencia del VIH

Investigadores del Hospital Brigham & Women´s han descubierto que la inducción de la proteína antiapoptótica BIRC5 es esencial en la supervivencia de los linfocitos T CD4+ infectados por el VIH-1. Mediante el uso de una sofisticada técnica de proteómica basada en la espectrometría de masas cuantitativa, los científicos han determinado que la infección viral activa […]

Cuba - infomed - Red de Salud de Cuba

2-6-2018

Asocian el asma con el desarrollo de la enfermedad isquémica coronaria

Asocian el asma con el desarrollo de la enfermedad isquémica coronaria

Diversos estudios epidemiológicos han demostrado que existe una relación entre el asma, en particular la de inicio en la edad adulta, con un alto riesgo de desarrollo de la enfermedad isquémica coronaria. Pero, al menos un estudio canadiense, ha constatado que los pacientes tratados con un glucocorticoide inhalado de forma regular podía reducir hasta un […]

Cuba - infomed - Red de Salud de Cuba

30-5-2018

Nuevas claves para entender la variabilidad de los retrovirus

Nuevas claves para entender la variabilidad de los retrovirus

La retrotranscripción es un proceso por el que la información contenida en el ARN se traslada al ADN, gracias a la participación de unas proteínas denominadas retrotranscriptasas. Su descubrimiento en 1970 supuso la modificación del ‘dogma de la biología molecular’, un concepto muy arraigado en esa época según el cual la información contenida en los […]

Cuba - infomed - Red de Salud de Cuba

29-5-2018

Newly Added Guidance Documents

Newly Added Guidance Documents

Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.

FDA - U.S. Food and Drug Administration

17-5-2018

Orphan designation:  branaplam,  for the: Treatment of spinal muscular atrophy

Orphan designation: branaplam, for the: Treatment of spinal muscular atrophy

Europe - EMA - European Medicines Agency

8-5-2018

Neurovascular Stents Used for Stent-Assisted Coiling (SAC): Letter to Health Care Providers - Recommendations Associated With the Use of These Devices in the Treatment of Unruptured Brain Aneurysms

Neurovascular Stents Used for Stent-Assisted Coiling (SAC): Letter to Health Care Providers - Recommendations Associated With the Use of These Devices in the Treatment of Unruptured Brain Aneurysms

The FDA has received reports associated with the use of these devices in the treatment of unruptured brain aneurysms that suggest some events of peri-procedural stroke and/or death may have been related to procedural risks or patient selection related factors. These factors include patients who had serious co-morbidities resulting in a reduced life expectancy, or who were intolerant to required anticoagulation or anti-platelet therapy.

FDA - U.S. Food and Drug Administration

29-3-2018

Seasonal Allergies: Which Medication is Right for You?

Seasonal Allergies: Which Medication is Right for You?

The FDA regulates many products that treat allergies or offer allergy relief. But which will work for you depends on your particular symptoms.

FDA - U.S. Food and Drug Administration

21-9-2018

Regulatory and procedural guideline:  Draft qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device, draft: consultation open

Regulatory and procedural guideline: Draft qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device, draft: consultation open

This report provides a final agreed draft Context of Use for public consultation describing where Stride Velocity measured at the ankle 95th Centile is deemed by CHMP as an appropriate endpoint in studies to support regulatory decision making on medicines for the treatment of Duchenne Muscular Dystrophy (DMD), together with CHMP’s scientific consideration of the submission leading to the draft opinion. The document also includes the questions posed by the applicant and also raised by CHMP to the Applic...

Europe - EMA - European Medicines Agency

19-9-2018

Lartruvo (Eli Lilly Nederland B.V.)

Lartruvo (Eli Lilly Nederland B.V.)

Lartruvo (Active substance: olaratumab) - Centralised - Annual renewal - Commission Decision (2018)6105 of Wed, 19 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4216/R/10

Europe -DG Health and Food Safety

28-8-2018

EU/3/18/2069 (Professor Marjukka MyllArniemi)

EU/3/18/2069 (Professor Marjukka MyllArniemi)

EU/3/18/2069 (Active substance: Tilorone) - Orphan designation - Commission Decision (2018)5738 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/039/18

Europe -DG Health and Food Safety

28-8-2018

Webinar: New warning statements on labels of neuromuscular blocking agents

Webinar: New warning statements on labels of neuromuscular blocking agents

Webinar providing an update on new warning statements on labels of neuromuscular blocking agents (NMBAs)

Therapeutic Goods Administration - Australia

10-7-2018

Ninlaro (Takeda Pharma A/S)

Ninlaro (Takeda Pharma A/S)

Ninlaro (Active substance: ixazomib) - Centralised - Yearly update - Commission Decision (2018)4463 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety

29-6-2018

New warnings on labels of medicines containing neuromuscular blocking agents

New warnings on labels of medicines containing neuromuscular blocking agents

New requirements for neuromuscular blocking agent containing medicines come into effect on 2 July

Therapeutic Goods Administration - Australia

19-6-2018

Neoclarityn (Merck Sharp and Dohme Limited)

Neoclarityn (Merck Sharp and Dohme Limited)

Neoclarityn (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3931 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/314/T/88

Europe -DG Health and Food Safety

6-6-2018

Update: Increased application audit requirements for some medical devices applications

Update: Increased application audit requirements for some medical devices applications

TGA no longer considers it necessary to apply increased audit requirements to particular European notified bodies for medical devices.

Therapeutic Goods Administration - Australia

3-5-2018

Atriance (Novartis Europharm Limited)

Atriance (Novartis Europharm Limited)

Atriance (Active substance: nelarabine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2780 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/752/T/41

Europe -DG Health and Food Safety